LivaNova (Nasdaq:LIVN) announced today that its board of directors appointed Brooke Story to its board as a new director. Story currently serves as worldwide president, of integrated diagnostic solutions at BD (NYSE:BD). Her appointment to LivaNova’s board is effective today, Sept. 15, 2022. She will also be a member of the board’s nominating and corporate […]
LivaNova
LivaNova stock up on Street-beating Q2 results
LivaNova (Nasdaq:LIVN) shares are up today on second-quarter results that topped the consensus forecast. The London-based company posted profits of $16.4 million, or 30¢ per share, on sales of $254.2 million for the three months ended June 30, 2022, for a massive bottom-line gain out of the red on a sales decline of 3.9% Adjusted […]
LivaNova launches patient monitor for cardiopulmonary bypass procedures
Livanova (Nasdaq:LIVN) announced today that it began the commercial launch of its Essenz patient monitor. London-based LivaNova launched the Essenz patient monitor in the U.S. and Europe, having recently received both FDA 510(k) clearance and CE mark approval. The monitor uses a patient-tailored approach to improve efficiency and quality of care during cardiopulmonary bypass (CPB) […]
LivaNova implants first patient in Osprey obstructive sleep apnea study
LivaNova (NSDQ:LIVN) announced that it completed the first patient implant in a study of its LivaNova aura6000 system. London-based LivaNova designed the aura6000 system to maintain muscle tone of the tongue and upper airway so that airway obstruction and resulting sleep apnea are significantly reduced or eliminated. The hypoglossal neurostimulator system includes a programmable, rechargeable […]
LivaNova stock up on Street-beating Q4
LivaNova (Nasdaq: LIVN) today reported fourth-quarter results that beat the consensus forecast on Wall Street, with sales expected to grow in 2022. The London-based cardiac surgery and neuromodulation device company lost $5.1 million, or 10¢ per share, off $270.1 million in sales for the quarter ended Dec. 31, 2021 — versus a loss of $281.1, […]
LivaNova skyrockets on Street-beating Q3 results
LivaNova (NSDQ:LIVN) today posted third-quarter results that beat the overall consensus on Wall Street. The London-based company reported losses of $42,000,000, or 82¢ per share, on sales of $253.2 million for the three months ended Sept. 30, for sales growth of 5.46% from Q3 2020. Adjusted to exclude one-time items, earnings per share were 68¢, 24¢ […]
LivaNova is up on Street-beating Q2 results
LivaNova (NSDQ:LIVN) today posted second-quarter results that beat the overall consensus on Wall Street and announced that it has taken the “interim” out of its CFO’s title. The London-based cardiac surgery and neuromodulation device company reported losses of –$55.3 million, or –$1.13 per share, on sales of $264.5 million for the three months ended June […]
MedTech 100 roundup: Rebound hits a snag
Two weeks ago, medtech was on the rise following a rough stretch, but the past week brought the industry slightly back down to earth. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week (June 4) at 106.96 points, producing a -1.4% dip from the 108.5-point mark […]
LivaNova moves forward with heart valve business sale
LivaNova (NSDQ:LIVN) announced today that it completed the initial closing of the sale of its heart valve business to Gyrus Capital. In December, LivaNova announced its board’s unanimous approval of the divestiture of the heart valve business to enable the company to “sharpen its focus” within its primary platforms, such as neuromodulation and cardiovascular. According […]
LivaNova rises on Street-beating Q1
LivaNova (NSDQ:LIVN) shares got a boost this morning on first-quarter results that beat the consensus forecast. LIVN shares were up 6.1% at $87.95 per share in early-morning trading today. The London-based company posted losses of -$29.7 million, or -61¢ per share, on sales of $247.6 million for the three months ended March 31, 2021, for […]
LivaNova gains FDA clearance for heart-lung machine
LivaNova (NSDQ:LIVN) announced today that it received FDA 510(k) clearance for its B-Capta system integrated into the S5 heart-lung machine. London-based LivaNova’s B-Capta, a new, in-line, blood-gas monitoring system is to be integrated into the S5 HLM to easily and accurately monitor arterial and venous blood gas parameters even during long and complex pediatric and […]